Next Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July.

New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes.

As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University.

I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.